Wednesday, January 24, 2007 2:47:03 PM
folks take a look at BLFS news today:
Jan 23, 2007 07:30:00 (ET)
OWEGO, N.Y., Jan 23, 2007 /PRNewswire-FirstCall via COMTEX/ -- BioLife Solutions Inc. (BLFS, Trade ) a leading manufacturer of proprietary cryopreservation media for cells and tissues, today announced preliminary results for product sales for the fourth quarter and full-year 2006.
Sales of the Company's patented HypoThermosol(R) and CryoStor(TM) preservation solutions for the quarter ended December 31, 2006, increased to $176,000, up 32 percent over fourth-quarter 2005. Full-year 2006 product sales increased 36 percent to $603,000, when compared to product sales for full-year 2005.
Chief Executive Officer Mike Rice commented: "Our product sales reflect increases in orders from both new and existing customers, which are attributable to our sales and marketing initiatives throughout 2006 and what we believe is growing adoption of HypoThermosol and CryoStor as cell therapy companies, pharmaceutical firms, and cell suppliers to academic research become more aware of the benefits of our products.
"As for our future growth, we have identified several new markets and applications for our products," Rice continued. "To help maximize the potential these opportunities offer, it's important that we strengthen and broaden our scientific team and expand our IP portfolio. We expect to be making several announcements over the next several weeks as we move forward with our growth plans, including the filing of several new patent applications."
The company also announced management changes. Its board of directors terminated the employment of John G. Baust, as chairman, senior vice president, and chief scientific officer pursuant to the terms of his employment agreement dated July 26, 2006, which includes a non-compete, non-solicitation clause effective for 24 months. The board of directors also terminated the employment of John M. Baust as the Company's director of research and development. He is the son of John G. Baust.
In a related decision, the board also elected to not renew its research and development agreement with Cell Preservation Services, Inc. (CPSI), which is scheduled to expire on March 15, 2007. The agreement with CPSI includes a non-disclosure provision that remains in force for 24 months and also specifies that BioLife owns all rights, titles, and interests in any and all technology, inventions, designs, and ideas that resulted from CPSI's research and development activities in support of specific projects directed by BioLife.
The Company has commenced searches for a new senior scientific officer and research and development officer as part of its strategic decision to bring its intellectual property and product development in-house.
About BioLife Solutions
BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) preservation media are marketed directly to companies, laboratories, and academic institutions engaged in research and commercial clinical applications. BioLife's line of serum-free and protein-free preservation solutions are fully defined and formulated to reduce or prevent preservation-induced, delayed-onset cell damage and death. BioLife's platform enabling technology provides academic and clinical researchers significant improvement in post-thaw cell, tissue, and organ viability and function. For more information please visit BioLife Solutions' website at www.biolifesolutions.com .
__________________________________
LISTEN UP FOLKS ....
PPMD is in the same field with probably better annual sales and a profit on the bottom line - although i cant confirm because i dont have a copy of the latest financials. you can find their filings under Celox labs.
check out their product line which is similar to that of BLFS - here it is from their website:http://www.protidepharma.com/default.aspx
______________
TCM
General purpose serum replacement for many cell types from a variety of species. The bovine albumin and transferrin are highly purified and heat treated. The final total protein concentration is less than 0.1%. For cell culture use. Not for human use. * TCM is packaged as a 50X concentrate.
See References
Catalog No. 1001 size 40ml – produces 2 liters of complete growth medium
Catalog No. 1002 size 100ml – produces 5 liters of complete growth medium
Catalog No. 2005 size 500ml produces 25 liters of complete medium
Custom Sizes Available – Please contact Customer Service for information
TM-235 ™
Has similar properties as TCM, however, contains additional components for cells which require serum concentrations (e.g. fetal bovine serum) higher than 10%. The final total protein concentration is less than 0.1%. The bovine albumin and transferrin are highly purified and heat treated. For cell culture use. Not for human use. TM-235 is packaged as a 50X concentrate.
See References
Catalog No. 2001 size 40ml produces 2 liters of complete medium
Catalog No. 2002 size 100ml produces 5 liters of complete medium
Catalog No. 2005 size 500ml produces 25 liters of complete medium
Custom Sizes Available – Please contact Customer Service for information
TCH ™
Primarily for human cells and the production of cell secreted proteins. TCH is also effective in culturing other mammalian cells without the use of animal proteins. For cell culture use. Not for human use. TCH is packaged as a 50X concentrate.
See References
Catalog No. 3001 size 40ml produces 2 liters of complete medium
Catalog No. 3002 size 100ml produces 5 liters of complete medium
Catalog No. 3005 size 500ml produces 25 liters of complete medium
Custom Sizes Available – Please contact Customer Service for information
pZerve ™
Is a cryopreservation solution that does not contain dimethyl sulfoxide (DMSO), fetal bovine serum or other animal protein. Optimal recovery is achieved through elimination of these harmful components. pZerve is ready to use, does not require any dilution or further processing and can be used for cells cultured in serum free medium or with serum containing medium. For research use.
See References
Catalog No. 5700 size 60ml
Custom Sizes Available – Please contact Customer Service for information
Cellvation ™
Is a unique cryopreservation medium which eliminates the problems associated with DMSO such as cytotoxicity, morphological differentiation and the adventitious components found in serum. Cellvation ™ is convenient to use, provides optimal recovery while eliminating preparation and centrifugation steps and can be used for cells cultured in serum free medium or with serum containing medium. For research use.
________________________
PPMD and BLFS are both in the same field.
i would be willing to wager that PPMD is doing much better than BLFS - and fwiw i own both stocks.
the problem i see is that BLFS has a market cap of over 5 million dollars with its 68 million plus shares OS whereas PPMD has a market cap of only 640k at the current bid. if PPMD had the same market cap as BLFS [which i believe it should and will] then it would be trading at $1.25
IF PPMD DOES NOT MAKE IT TO $1.25 I WILL EAT A FLEA!
the Professor
Jan 23, 2007 07:30:00 (ET)
OWEGO, N.Y., Jan 23, 2007 /PRNewswire-FirstCall via COMTEX/ -- BioLife Solutions Inc. (BLFS, Trade ) a leading manufacturer of proprietary cryopreservation media for cells and tissues, today announced preliminary results for product sales for the fourth quarter and full-year 2006.
Sales of the Company's patented HypoThermosol(R) and CryoStor(TM) preservation solutions for the quarter ended December 31, 2006, increased to $176,000, up 32 percent over fourth-quarter 2005. Full-year 2006 product sales increased 36 percent to $603,000, when compared to product sales for full-year 2005.
Chief Executive Officer Mike Rice commented: "Our product sales reflect increases in orders from both new and existing customers, which are attributable to our sales and marketing initiatives throughout 2006 and what we believe is growing adoption of HypoThermosol and CryoStor as cell therapy companies, pharmaceutical firms, and cell suppliers to academic research become more aware of the benefits of our products.
"As for our future growth, we have identified several new markets and applications for our products," Rice continued. "To help maximize the potential these opportunities offer, it's important that we strengthen and broaden our scientific team and expand our IP portfolio. We expect to be making several announcements over the next several weeks as we move forward with our growth plans, including the filing of several new patent applications."
The company also announced management changes. Its board of directors terminated the employment of John G. Baust, as chairman, senior vice president, and chief scientific officer pursuant to the terms of his employment agreement dated July 26, 2006, which includes a non-compete, non-solicitation clause effective for 24 months. The board of directors also terminated the employment of John M. Baust as the Company's director of research and development. He is the son of John G. Baust.
In a related decision, the board also elected to not renew its research and development agreement with Cell Preservation Services, Inc. (CPSI), which is scheduled to expire on March 15, 2007. The agreement with CPSI includes a non-disclosure provision that remains in force for 24 months and also specifies that BioLife owns all rights, titles, and interests in any and all technology, inventions, designs, and ideas that resulted from CPSI's research and development activities in support of specific projects directed by BioLife.
The Company has commenced searches for a new senior scientific officer and research and development officer as part of its strategic decision to bring its intellectual property and product development in-house.
About BioLife Solutions
BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) preservation media are marketed directly to companies, laboratories, and academic institutions engaged in research and commercial clinical applications. BioLife's line of serum-free and protein-free preservation solutions are fully defined and formulated to reduce or prevent preservation-induced, delayed-onset cell damage and death. BioLife's platform enabling technology provides academic and clinical researchers significant improvement in post-thaw cell, tissue, and organ viability and function. For more information please visit BioLife Solutions' website at www.biolifesolutions.com .
__________________________________
LISTEN UP FOLKS ....
PPMD is in the same field with probably better annual sales and a profit on the bottom line - although i cant confirm because i dont have a copy of the latest financials. you can find their filings under Celox labs.
check out their product line which is similar to that of BLFS - here it is from their website:http://www.protidepharma.com/default.aspx
______________
TCM
General purpose serum replacement for many cell types from a variety of species. The bovine albumin and transferrin are highly purified and heat treated. The final total protein concentration is less than 0.1%. For cell culture use. Not for human use. * TCM is packaged as a 50X concentrate.
See References
Catalog No. 1001 size 40ml – produces 2 liters of complete growth medium
Catalog No. 1002 size 100ml – produces 5 liters of complete growth medium
Catalog No. 2005 size 500ml produces 25 liters of complete medium
Custom Sizes Available – Please contact Customer Service for information
TM-235 ™
Has similar properties as TCM, however, contains additional components for cells which require serum concentrations (e.g. fetal bovine serum) higher than 10%. The final total protein concentration is less than 0.1%. The bovine albumin and transferrin are highly purified and heat treated. For cell culture use. Not for human use. TM-235 is packaged as a 50X concentrate.
See References
Catalog No. 2001 size 40ml produces 2 liters of complete medium
Catalog No. 2002 size 100ml produces 5 liters of complete medium
Catalog No. 2005 size 500ml produces 25 liters of complete medium
Custom Sizes Available – Please contact Customer Service for information
TCH ™
Primarily for human cells and the production of cell secreted proteins. TCH is also effective in culturing other mammalian cells without the use of animal proteins. For cell culture use. Not for human use. TCH is packaged as a 50X concentrate.
See References
Catalog No. 3001 size 40ml produces 2 liters of complete medium
Catalog No. 3002 size 100ml produces 5 liters of complete medium
Catalog No. 3005 size 500ml produces 25 liters of complete medium
Custom Sizes Available – Please contact Customer Service for information
pZerve ™
Is a cryopreservation solution that does not contain dimethyl sulfoxide (DMSO), fetal bovine serum or other animal protein. Optimal recovery is achieved through elimination of these harmful components. pZerve is ready to use, does not require any dilution or further processing and can be used for cells cultured in serum free medium or with serum containing medium. For research use.
See References
Catalog No. 5700 size 60ml
Custom Sizes Available – Please contact Customer Service for information
Cellvation ™
Is a unique cryopreservation medium which eliminates the problems associated with DMSO such as cytotoxicity, morphological differentiation and the adventitious components found in serum. Cellvation ™ is convenient to use, provides optimal recovery while eliminating preparation and centrifugation steps and can be used for cells cultured in serum free medium or with serum containing medium. For research use.
________________________
PPMD and BLFS are both in the same field.
i would be willing to wager that PPMD is doing much better than BLFS - and fwiw i own both stocks.
the problem i see is that BLFS has a market cap of over 5 million dollars with its 68 million plus shares OS whereas PPMD has a market cap of only 640k at the current bid. if PPMD had the same market cap as BLFS [which i believe it should and will] then it would be trading at $1.25
IF PPMD DOES NOT MAKE IT TO $1.25 I WILL EAT A FLEA!
the Professor
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
